A study in The Lancet Diabetes & Endocrinology showed that once-weekly injectable dulaglutide 0.75 mg and 1.5 mg were noninferior in terms of A1C decrease at week 26 and 52 and had a clear safety advantage based on an approximately 50% lower hypoglycemia rate, compared with daily insulin glargine. Researchers used a cohort of 577 patients with type 2 diabetes and moderate to severe chronic kidney disease and found that treatment with dulaglutide also resulted in a smaller decline in estimated glomerular filtration rate, a greater reduction in albuminuria and weight loss.
Study: Dulaglutide is safe, effective for patients with diabetes, CKD
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.